Status:
COMPLETED
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Lead Sponsor:
Bayer
Conditions:
Androgens (Deficiency)
Male
Eligibility:
MALE
50-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM. The effects on body composition (lean, fat and bone) and other symptoms ...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial...
Eligibility Criteria
Inclusion
- Symptomatic hypogonadism
- Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study
Exclusion
- Patients with any contraindication for testosterone use
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
363 Patients enrolled
Trial Details
Trial ID
NCT00185198
Start Date
September 1 2004
End Date
October 1 2007
Last Update
April 2 2014
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Vienna, Austria, 1090
2
Graz, Austria, 8036
3
Innsbruck, Austria, 6020
4
Salzburg, Austria, 5020